- Ariad Pharmaceuticals (ARIA -3.6%) began the day in the red and has traded steadily lower throughout the session.
- Perhaps weighing on the shares is the news that Clovis Oncology (CLVS -11.1%) has received no interest from buyers after hiring Credit Suisse to explore strategic options.
- Like CLVS' lead compound CO-1686, ARIA's AP26113 is an EGFR inhibitor.
- When news hit last week that CLVS was pursuing a sale, ARIA spiked.
From other sites
at CNBC.com (Jan 16, 2015)
at CNBC.com (Jan 14, 2015)
Video at CNBC.com (Jan 13, 2015)
at CNBC.com (Jan 13, 2015)
at CNBC.com (Jan 9, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs